Last reviewed · How we verify
68Ga-DOTATOC
68Ga-DOTATOC is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, enabling their detection and localization via positron emission tomography (PET) imaging.
68Ga-DOTATOC is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, enabling their detection and localization via positron emission tomography (PET) imaging. Used for Imaging of somatostatin receptor-positive neuroendocrine tumors (NET), Gastroenteropancreatic neuroendocrine tumors (GEP-NET), Neuroendocrine tumor detection and staging.
At a glance
| Generic name | 68Ga-DOTATOC |
|---|---|
| Also known as | Diagnostic test |
| Sponsor | Montefiore Medical Center |
| Drug class | Radiolabeled somatostatin receptor agonist; PET imaging agent |
| Target | Somatostatin receptor 2 (SSTR2); somatostatin receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology; Nuclear Medicine/Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
DOTATOC is a somatostatin receptor-targeting peptide conjugated to gallium-68, a positron-emitting radioisotope. The peptide binds with high affinity to somatostatin receptor subtype 2 (SSTR2) and other somatostatin receptors expressed on neuroendocrine tumors. The gallium-68 radiolabel allows real-time visualization of tumor location and burden via PET imaging, facilitating diagnosis, staging, and treatment planning.
Approved indications
- Imaging of somatostatin receptor-positive neuroendocrine tumors (NET)
- Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- Neuroendocrine tumor detection and staging
Common side effects
- Radiation exposure (minimal; diagnostic dose)
- Allergic reaction to peptide
- Injection site reactions
Key clinical trials
- Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome (PHASE2)
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- Studies on Tumors of the Thyroid
- Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors (NA)
- The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer (PHASE2)
- Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |